Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors. After a 1-week, three-...
| Publicado en: | European Radiology Vol. 19; no. 1; pp. 121 - 132 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Jan2009
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105624539&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105624539 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09387994 NPH jtl: European Radiology issn: 09387994 maglogo: N pubinfo: dt: Jan2009 vid: 19 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105624539 105624539 36145909 NLM18665367 2010167819 10.1007/s00330-008-1111-x NLM18665367 105624539 ppf: 121 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. aug: au: Cyran CC Sennino B Chaopathomkul B Fu Y Rogut VS Shames DM Wendland MF McDonald DM Brasch RC Cyran, Clemens C Sennino, Barbara Chaopathomkul, Bundit Fu, Yanjun Rogut, Victor S Shames, David M Wendland, Michael F McDonald, Donald M Brasch, Robert C affil: Center for Pharmaceutical and Molecular Imaging, Department of Radiology, University of California San Francisco, San Francisco, CA 94143-0628, USA sug: subj: Breast Neoplasms Diagnosis Breast Neoplasms Drug Therapy Magnetic Resonance Imaging Methods Models, Biological Thalidomide Administration and Dosage Angiogenesis Inhibitors Administration and Dosage Animal Studies Prognosis Rats Reproducibility of Results Sensitivity and Specificity Treatment Outcomes ab: Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors. After a 1-week, three-dose course of thalidomide, the mean MRI-assayed endothelial transfer coefficient, K(PS), decreased significantly (p < 0.05) from 19.4 +/- 9.1 to 6.3 +/- 9.1 microl/min.100 cm(3). Correspondingly, microscopic measurements of extravasated MMCM, expressed as fractional area of streptavidin staining, were significantly (p < 0.05) lower in thalidomide-treated tumors (18.6 +/- 11.9%) than in control saline-treated tumors (50.2 +/- 2.3%). On a tumor-by-tumor basis, post-treatment K(PS) values correlated significantly (r(2) = 0.55, p < 0.05) with microscopic measures of MMCM extravasation. However, no significant differences were observed between saline- and thalidomide-treated tumors with respect to rate of growth, vascular richness, or amount of VEGF-containing cells. Because of its sensitivity to the detection of changes in vascular leakage in tumors, this MMCM-enhanced MRI assay could prove useful for monitoring the effects of thalidomide on an individual patient basis. The significant correlation between MRI and fluorescence microscopic measures of MMCM extravasation supports the utility of the non-invasive MRI approach for assessing the action of thalidomide on tumor blood vessels. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|